Biotech Short Interest NOV 2007 II (AMGN, BIIB, CELG, GENZ, GILD, IMCL, MEDX)

Health and Healthcare

Published: December 11, 2007 5:30 pm

We’ve had a lot of biotech stocks see their shares get the wrath of news over recent days. Now that the November-end NASDAQ Short Interest has been released, we wanted to see how the gains and losses were in short selling activity. Here is the key short selling data on NASDAQ as of November 27, 2007 and Settlement Date of November 30, 2007:

STOCK (Ticker)       Shares Short Change
Amgen (AMGN)       29,112,550    +10.89%
Biogen Idec (BIIB)    6,648,180       (9.58%)
Celgene (CELG)    25,751,400    +12.19%
Genzyme (GENZ)    6,536,150       +12.36%
Gilead (GILD)          25,557,168       (1.59%)
Imclone (IMCL)       4,252,342       (13.49%)
Medarex (MEDX)       30,181,760    (7.72%)

As a reminder, Biogen Idec was the one that Wall Street feels is close to being acquired because of its review being announced.

Jon C. Ogg
December 11, 2007

Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.

Smart Investors Are Quietly Loading Up on These “Dividend Legends”

If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.

Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.